Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
4.520
+0.190 (4.39%)
At close: Oct 16, 2026, 4:00 PM EDT
4.584
+0.064 (1.41%)
After-hours: Oct 16, 2026, 7:30 PM EDT
Corbus Pharmaceuticals Holdings Employees
Corbus Pharmaceuticals Holdings had 36 employees as of December 31, 2025. The number of employees increased by 8 or 28.57% compared to the previous year. That makes Corbus Pharmaceuticals Holdings the 36,354th largest employer in the world and 5,012th in the United States.
Employees
36
Change (1Y)
8
Growth (1Y)
28.57%
Revenue / Employee
n/a
Profits / Employee
-$2,830,639
Market Cap
87.42M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 36 | 8 | 28.57% |
| Dec 31, 2024 | 28 | 9 | 47.37% |
| Dec 31, 2023 | 19 | -14 | -42.42% |
| Dec 31, 2022 | 33 | -8 | -19.51% |
| Dec 31, 2021 | 41 | -35 | -46.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| Immunic | 100 |
| Tenaya Therapeutics | 70 |
| OnKure Therapeutics | 45 |
| Aardvark Therapeutics | 28 |
| NeurAxis | 24 |
| Tenax Therapeutics | 16 |
| Equillium | 15 |
CRBP News
- 18 days ago - Corbus announces first patient dosed in TEMPO-1 study of CRB-701 - TheFly
- 18 days ago - Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer - GlobeNewsWire
- 4 weeks ago - Corbus Pharmaceuticals Holdings Transcript: Study result - Transcripts
- 4 weeks ago - Corbus Pharmaceuticals Holdings Press release: Study result - Filings
- 4 weeks ago - Corbus Pharmaceuticals Holdings Slides: Study result - Filings
- 4 weeks ago - Corbus Pharmaceuticals announces topline data from CANYON-1 trial - TheFly
- 4 weeks ago - Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity - GlobeNewsWire